Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Ruth Ann, Subach"'
Autor:
Filip Janku, Milind M. Javle, Shiraj Sen, Shubham Pant, Lindsay G. Bramwell, Vivek Subbiah, Tracey Way, David S. Wages, Catherine A. Wheeler, Takeaki Suzuki, Kazunori Saeki, Ruth Ann Subach, Timothy Madden, Gary Maier, Mary J. Johansen, Kin Cheung, Gerald S. Falchook
Publikováno v:
Cancer. 129:1537-1546
Autor:
Gregory Ravizzini, Satoshi Matsushima, Yuichi Funase, Eri Nakamura, Masamichi Kajita, Tadashi Matsuura, Hirokazu Satoh, Fumiko Nomura, Mary Johansen, Timothy Madden, Ruth Ann Subach, Takeaki Suzuki, Jason Roszik, Jose Gonzalez, Elmer Santos, Dao Le, Shubham Pant, David S. Hong, Funda Meric-Bernstam, Homer Macapinlac, Holly Liu, Carlos Gonzalez-Lepera, Catherine Wheeler, David Wages, Asa McCoy, Osama Mawlawi, William Erwin, Vivek Subbiah
Purpose:90Y-FF-21101 is an Yttrium-90–conjugated, chimeric mAb that is highly specific for binding to human placental (P)-cadherin, a cell-to-cell adhesion molecule overexpressed and associated with cancer invasion and metastatic dissemination in m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::202aafe290dbe92efdbacbf6b0e01223
https://doi.org/10.1158/1078-0432.c.6529733.v1
https://doi.org/10.1158/1078-0432.c.6529733.v1
Autor:
Gregory Ravizzini, Satoshi Matsushima, Yuichi Funase, Eri Nakamura, Masamichi Kajita, Tadashi Matsuura, Hirokazu Satoh, Fumiko Nomura, Mary Johansen, Timothy Madden, Ruth Ann Subach, Takeaki Suzuki, Jason Roszik, Jose Gonzalez, Elmer Santos, Dao Le, Shubham Pant, David S. Hong, Funda Meric-Bernstam, Homer Macapinlac, Holly Liu, Carlos Gonzalez-Lepera, Catherine Wheeler, David Wages, Asa McCoy, Osama Mawlawi, William Erwin, Vivek Subbiah
Supplemental files for "Phase 1 Study of P-cadherin-Targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors" Subbiah V et al.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95071a111f84f2a1837002a47b5e95bd
https://doi.org/10.1158/1078-0432.22477688.v1
https://doi.org/10.1158/1078-0432.22477688.v1
Autor:
Satoshi Matsushima, Tadashi Matsuura, Fumiko Nomura, Catherine Wheeler, Jason Roszik, Ruth Ann Subach, Dao B. Le, Eri Nakamura, Masamichi Kajita, Hirokazu Satoh, David S. Hong, Timothy Madden, Homer A. Macapinlac, Mary Johansen, Osama Mawlawi, Vivek Subbiah, William D. Erwin, Hui Liu, Shubham Pant, Carlos Gonzalez-Lepera, Asa McCoy, Jose Gonzalez, Takeaki Suzuki, David Wages, Elmer B Santos, Gregory Ravizzini, Funda Meric-Bernstam, Yuichi Funase
Publikováno v:
Clinical Cancer Research. 26:5830-5842
Purpose: 90Y-FF-21101 is an Yttrium-90–conjugated, chimeric mAb that is highly specific for binding to human placental (P)-cadherin, a cell-to-cell adhesion molecule overexpressed and associated with cancer invasion and metastatic dissemination in
Autor:
Ursula A. Matulonis, Filip Janku, Justin C Moser, Siqing Fu, David S. Wages, Catherine A. Wheeler, Mikinaga Mori, Susumu Shimoyama, Naoki Yamada, Ruth Ann Subach, Kin Cheung, Timothy Madden, Gary Maier, Mary Johansen, Gerald Steven Falchook
Publikováno v:
Journal of Clinical Oncology. 40:3101-3101
3101 Background: FF-10850 (liposomal topotecan) was developed using a unique dihydrosphingomyelin-based carrier to enhance tumor drug delivery and retention, leading to improved efficacy and safety. Preclinical studies demonstrated superior anti-tumo
Autor:
Erkut Hasan Borazanci, Filip Janku, Erika P. Hamilton, Jacob Stephen Thomas, Shiraj Sen, Siqing Fu, Catherine A. Wheeler, David S. Wages, Takeshi Matsumoto, Susumu Shimoyama, Naoki Yamada, Ruth Ann Subach, Timothy Madden, Mary Johansen, Gary Maier, Kin Cheung, Ron Korn, Gerald Steven Falchook
Publikováno v:
Journal of Clinical Oncology. 40:3097-3097
3097 Background: FF-10832 is a stable liposomal formulation of gemcitabine (GEM) shown to overcome resistance through increased plasma stability and enhanced tumor drug delivery. Macrophage uptake and immune activation in the tumor microenvironment (
Autor:
Vivek, Subbiah, William, Erwin, Osama, Mawlawi, Asa, McCoy, David, Wages, Catherine, Wheeler, Carlos, Gonzalez-Lepera, Holly, Liu, Homer, Macapinlac, Funda, Meric-Bernstam, David S, Hong, Shubham, Pant, Dao, Le, Elmer, Santos, Jose, Gonzalez, Jason, Roszik, Takeaki, Suzuki, Ruth Ann, Subach, Timothy, Madden, Mary, Johansen, Fumiko, Nomura, Hirokazu, Satoh, Tadashi, Matsuura, Masamichi, Kajita, Eri, Nakamura, Yuichi, Funase, Satoshi, Matsushima, Gregory, Ravizzini
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(22)
The safety and efficacy ofThe favorable safety profile and initial antitumor activity observed for
Autor:
Ruth Ann Subach, David G. Soergel, Harold S. Minkowitz, Neil Singla, David A. Burt, Michael J. Fossler, Monica Y Salamea, Franck Skobieranda
Publikováno v:
Journal of Pain Research
Neil Singla,1 Harold S Minkowitz,2 David G Soergel,3 David A Burt,3 Ruth Ann Subach,3 Monica Y Salamea,3 Michael J Fossler,3 Franck Skobieranda3 1Lotus Clinical Research, Pasadena, CA, 2Memorial Hermann Memorial City Medical Center, Houston, TX, 3Tre
Autor:
Timothy Madden, Jessica K. Altman, Alexander E. Perl, Gary J. Schiller, Makoto Ando, Takeaki Suzuki, Catherine C. Smith, Mark J. Levis, Eunice S. Wang, Gail J. Roboz, Amir T. Fathi, Mary Johansen, Ruth Ann Subach, Michael R. Kurman, Kin Yin Cheung, Gary Maier
Publikováno v:
Journal of Clinical Oncology. 39:7008-7008
7008 Background: FF-10101-01 is a selective and irreversible FMS-like tyrosine kinase 3 (FLT3) inhibitor with potent in vitro activity against FLT3-mutated AML. FF-10101-01 is highly active against FLT3 internal tandem duplication (ITD) mutations ass
Autor:
Timothy Madden, Catherine Wheeler, Kin Yin Cheung, Vivek Subbiah, Satoshi Matsushima, David S. Wages, Debra L. Richardson, Takeaki Suzuki, Ruth Ann Subach, Devalingam Mahalingam, Aparna Kalyan, Taofeek K. Owonikoko, Susanna Varkey Ulahannan, Mary Johansen, Mary F. Mulcahy
Publikováno v:
Journal of Clinical Oncology. 39:78-78
78 Background: Overexpression of the cell-cell adhesion protein P-cadherin has been associated with a more aggressive cancer cell phenotype, cancer stem cell properties, tumor invasion and metastasis. We determined the safety and recommended Phase II